Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Primary Myelofibrosis 1Myelodysplastic-Myeloproliferative Diseases 1Immune Checkpoint Inhibitors (ICI)-Related Dermatitis 1

Interventions

Specimen Handling 3Azacitidine 3ruxolitinib 2Melphalan 2Cyclophosphamide 2Busulfan 2Biopsy 2venetoclax 1posaconazole 1onvansertib 1merphos 1gilteritinib 1fludarabine phosphate 1fludarabine 1fedratinib 1axatilimab 1Whole-Body Irradiation 1Watchful Waiting 1Tranexamic Acid 1Tacrolimus 1Succimer 1Stem Cell Transplantation 1Rituximab 1Positron-Emission Tomography 1Pentetic Acid 1Methotrexate 1Janus Kinase Inhibitors 1Injections 1Hyperbaric Oxygenation 1High-Energy Shock Waves 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Myelodysplastic-Myeloproliferative Diseases × Janus Kinase Inhibitors × Clear all
NCT07228624 2026-02-19

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Fred Hutchinson Cancer Center

Phase 2 Recruiting
50 enrolled
Myeloid

Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡